<DOC>
	<DOCNO>NCT02223208</DOCNO>
	<brief_summary>This multicenter study include two phase : 1 . A phase I study define maximum tolerate dose ( MTD ) Romidepsin addition CHOEP-21 test safety feasibility CHOEP-21 combination dose escalation Romidepsin ( 8 , 10 , 12 , 14 mg ) . The dose level define MTD Romidepsin use subsequent phase II study . 2 . A phase II study evaluate efficacy ( response rate , progression free survival overall survival ) safety Ro-CHOEP-21 incorporated treatment strategy include SCT .</brief_summary>
	<brief_title>Romidepsin Combination With CHOEP First Line Treatment Before Hematopoietic Stem Cell Transplantation Young Patients With Nodal Peripheral T-cell Lymphomas : Phase I-II Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . Age ≥18 e ≤ 65 year 2 . Peripheral Tcell lymphomas diagnosis include : PTCLNOS , AITL , ALKALCL 3 . Stage IIIV 4 . Written inform consent 5 . No prior treatment lymphoma 6 . No Central Nervous System ( CNS ) disease ( meningeal and/or brain involvement lymphoma ) 7 . HIV negativity 8 . Absence active hepatitis C virus ( HCV ) infection 9 . HBV negativity patient HBcAb + , HBsAg , HBs Ab+/ HBVDNA negativity ( patient Lamivudine prophylaxis mandatory ) 10 . Levels serum bilirubin , alkaline phosphatase transaminases &lt; 2 upper normal limit , disease relate 11 . No psychiatric illness precludes understanding concept trial signing inform consent 12 . Ejection fraction &gt; 50 % myocardial stroke last year QT prolongation ( QTc interval &lt; 480 msec use Fridericia formula ) 13 . Clearance creatinine &gt; 60 ml/min disease relate 14 . Spirometry Diffusion Capacity ( DLCO ) &gt; 50 % 15 . Absence active , uncontrolled infection 16 . For male female childbearing potential , agreement upon use effective contraceptive method prior study entry , duration study participation follow 90 day discontinuation study treatment 17 . Availability histological material central review pathobiological study . 1 . Age &lt; 18 e &gt; 65 year 2 . Hystology : PTCLNOS , AITL , ALKALCL 3 . Stage I 4 . Prior treatment lymphoma 5 . Positive serologic marker human immunodeficiency virus ( HIV ) 6 . Active hepatitis B virus ( HBV ) infection 7 . Active hepatitis C virus ( HCV ) infection 8 . Levels serum bilirubin , alkaline phosphatase transaminases &gt; 2 upper normal limit , disease relate 9 . Ejection fraction &lt; 50 % myocardial stroke last year QT prolongation ( QTc interval &gt; 480 msec use Fridericia formula ) 10 . Clearance creatinine &lt; 60 ml/min disease relate 11 . Spirometry Diffusion Capacity ( DLCO ) &lt; 50 % 12 . Pregnancy lactation 13 . Patient agree take adequate contraceptive measure study 14 . Psychiatric disease precludes understanding concept trial signing inform consent 15 . Any active , uncontrolled infection 16 . Prior history malignancy PTCLs last five year ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PTCL</keyword>
	<keyword>PTCL-NOS</keyword>
	<keyword>AITL</keyword>
	<keyword>ALCL</keyword>
</DOC>